| Outcome Measures: |
Primary: HbA1c, From baseline to study endpoint|Self monitored BG (SMBG) values, During the whole treatment phase|Body weight/body mass index (BMI), From baseline to study endpoint and all other visits|Fasting blood lipid profile, From baseline to study endpoint and all other visits|Urine albumin, From baseline to study endpoint and all other visits|Total daily insulin dose, From baseline to study endpoint | Secondary: Adverse events, Throughout the study,|Standard laboratory tests, From baseline to study endpoint and all other visits|Vital signs, From baseline to study endpoint and all other visits|Physical examination, From baseline to study endpoint and all other visits
|
| Locations: |
Sanofi-Aventis, North Ryde, Australia|Sanofi-Aventis, Brussels, Belgium|Sanofi-Aventis, Prague, Czech Republic|Sanofi-Aventis, Paris, France|Sanofi-Aventis, Berlin, Germany|Sanofi-Aventis, Milan, Italy|Sanofi-Aventis, Gouda, Netherlands|Sanofi-Aventis, Warsaw, Poland|Sanofi-Aventis, Porto Salvo, Portugal|Sanofi-aventis, Bucharest, Romania|Sanofi-Aventis, Bratislava, Slovakia|Sanofi-Aventis, Barcelona, Spain|Sanofi-Aventis, Stockholm, Sweden|Sanofi-Aventis, Meyrin, Switzerland|Sanofi-Aventis, Guildford, United Kingdom
|
